Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fusion Pharmaceuticals Inc (FUSN)

Fusion Pharmaceuticals Inc (FUSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,833,043
  • Shares Outstanding, K 85,060
  • Annual Sales, $ 2,070 K
  • Annual Income, $ -94,900 K
  • EBIT $ -99 M
  • EBITDA $ -98 M
  • 60-Month Beta -0.69
  • Price/Sales 885.15
  • Price/Cash Flow N/A
  • Price/Book 7.58
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.47
  • Most Recent Earnings $-0.40 on 05/07/24
  • Next Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.37
  • Number of Estimates 6
  • High Estimate -0.28
  • Low Estimate -0.44
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +2.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.35 +0.94%
on 05/10/24
21.60 -0.23%
on 05/31/24
+0.10 (+0.47%)
since 05/03/24
3-Month
9.09 +137.07%
on 03/14/24
21.60 -0.23%
on 05/31/24
+9.56 (+79.73%)
since 03/01/24
52-Week
2.31 +832.90%
on 09/11/23
21.60 -0.23%
on 05/31/24
+16.65 (+339.80%)
since 06/02/23

Most Recent Stories

More News
Acquisition of Fusion Pharmaceuticals Completed

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

FUSN : 21.55 (+0.14%)
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster...

AZN : 65.35 (+1.41%)
FUSN : 21.55 (+0.14%)
NVS : 97.11 (+0.35%)
LLY : 767.76 (+1.35%)
BMY : 57.33 (+1.83%)
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

FUSN : 21.55 (+0.14%)
Stocks Recover on Lower Bond Yields and Strength in Energy Stocks

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.26%. Stocks on Tuesday...

$SPX : 5,930.85 (+1.09%)
SPY : 591.15 (+1.20%)
$DOWI : 42,840.26 (+1.18%)
DIA : 428.54 (+1.24%)
$IUXX : 21,289.15 (+0.85%)
QQQ : 518.66 (+0.87%)
^BTCUSD : 96,216.45 (-0.42%)
ZNH25 : 108-310s (+0.33%)
IP : 54.45 (+1.13%)
FUSN : 21.55 (+0.14%)
BKR : 40.32 (+1.31%)
APA : 21.04 (+2.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.

See More

Key Turning Points

3rd Resistance Point 21.75
2nd Resistance Point 21.67
1st Resistance Point 21.61
Last Price 21.55
1st Support Level 21.47
2nd Support Level 21.39
3rd Support Level 21.33

See More

52-Week High 21.60
Last Price 21.55
Fibonacci 61.8% 14.23
Fibonacci 50% 11.95
Fibonacci 38.2% 9.68
52-Week Low 2.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar